Understanding your insurance coverage is very important. Our CareConnectPSS® Case Managers are here to help you and your physician better understand your insurance benefits, so you can get access to the treatment you need. Sanofi Genzyme also offers co-pay assistance and charitable access programs for eligible patients.
A consent form is required for a CareConnectPSS Case Manager to work with you, your health care providers and insurance company. This service is offered at no cost to you and is completely voluntary. Any information you provide will be maintained as confidential by Sanofi Genzyme.
The Co-Pay Assistance Program helps individuals in the United States who are prescribed Lumizyme pay for their eligible out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including co-pays, co-insurance and deductibles.
To participate in this program you must complete an enrollment application. Once enrolled, Sanofi Genzyme will cover 100% of your eligible out-of-pocket Lumizyme drug costs up to the program maximum.
Download your application online today or to learn more about the program call , option 3.
Regardless of financial status, the program is open to individuals who:
You are NOT eligible if you:
Helpful information to have on hand when you apply:
Your application will be reviewed for eligibility. If you are eligible, you will be automatically enrolled in the program. Enrollment in the program is subject to confirmation of eligibility.
Once approved, you will receive confirmation letter and an enrollment card within 7-10 days. Contact your Case Manager if you do not receive this confirmation. Your doctor or specialty pharmacy will also receive a phone call with instructions on how to submit claims for reimbursement through the program. Your enrollment in the program is effective from the date of approval through the end of the calendar year (calendar year is January 1 through December 31).
If you are currently enrolled in our Co-Pay Assistance Program you will be automatically enrolled in the program for the next calendar year (January 1 through December 31) unless you decide to opt out of the program or your insurance coverage changes and you are no longer eligible for the program.
LUMIZYME® (alglucosidase alfa) is an enzyme replacement therapy for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).
WARNING: RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide you with immediate medical care. Appropriate medical support and monitoring measures should be available during infusion.
Immune-Mediated Reactions: You or your child may be monitored for the development of systemic immune-mediated reactions while receiving Lumizyme. If these reactions occur, your doctor may discontinue the infusion and initiate appropriate medical treatment.
Risk of Acute Cardiorespiratory Failure: Infant Pompe patients with heart or breathing problems who are experiencing an acute respiratory condition may be at risk for increasing the seriousness of these problems as a result of Lumizyme administration due to the infusion fluid, and your child’s doctor may require additional monitoring for these infants.
Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for Lumizyme infusion. Ventricular arrhythmias and slow heart rate resulting in cardiac arrest or death have been observed in infant Pompe patients with cardiac hypertrophy during general anesthesia for central venous catheter placement. Appropriate medical support and monitoring measures should be available during infusion.
Risk of Antibody Development: Patients with infantile-onset Pompe disease (IOPD) should be managed by a clinical specialist knowledgeable in immune tolerance induction in Pompe disease to optimize treatment. Some patients who develop high and sustained IgG antibody levels, including certain IOPD patients, may have a reduced response to Lumizyme.
Monitoring: Laboratory Tests: Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter.
The most frequently reported adverse reactions during Lumizyme studies in patients were allergy reactions and included: anaphylaxis, rash, fever, flushing/feeling hot, hives, headache, excessive sweating, nausea, cough, less oxygen in the blood, fast heart rate, rapid breathing, chest discomfort, dizziness, muscle twitching, agitation, bluish or purple skin, redness of skin, high blood pressure/increased blood pressure, facial paleness, chills, tremor, vomiting, fatigue, and muscle pain.
Please see the Full Prescribing Information for complete details, including boxed WARNING.